Market Cap (In TWD)
1.9 Billion
Revenue (In TWD)
43.49 Million
Net Income (In TWD)
-223.74 Million
Avg. Volume
151.32 Thousand
- Currency
- TWD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 25.6-49.3
- PE
- -
- EPS
- -
- Beta Value
- 0.515
- ISIN
- TW0006564008
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- -
- Employee Count
- -
- Website
- https://www.enimmune.com.tw
- Ipo Date
- 2018-09-18
- Details
- Enimmune corporation operates as a biopharmaceutical Research and development, and marketing company in Taiwan. Its products include Tuberculin PPD RT23 SSI, an approved drug for tuberculin test to determine whether the patient is infected with tuberculosis. The company is also involved in the development of vaccines to prevent various infectious diseases, such as enterovirus, pneumonia, norovirus, dengue fever virus, Middle East respiratory syndrome coronavirus, etc. Enimmune corporation was founded in 2014 and is based in Taichung City, Taiwan.
More Stocks
-
RAJOOENGRajoo Engineers Limited
RAJOOENG
-
CPT
-
IDEA
-
2886
-
COCMComerton Corp.
COCM
-
ED
-
LYV
-
ALCRBCarbios SAS
ALCRB